Gynecological Cancer Drugs Market By Therapeutic Modality (Chemotherapy, Targeted Therapy, Hormonal Therapy), By Indication (Cervical Cancer, Uterine Cancer, Ovarian Cancer, Vaginal & Vulvar Cancer): Global Opportunity Analysis and Industry Forecast, 2020-2030

Gynecological Cancer Drugs Market

Cancer progresses when normal body cells transform into abnormal cells and continue to grow in an uncontrolled manner. It is named after the body part in which it originates, so gynecological cancer refers to a group of cancers that affect the reproductive organs of a female. Gynecological cancers include cancer in the uterus, endometrium, ovary, peritoneum, fallopian tubes, vagina, vulva, cervix, and muscle &tissue supporting the uterus.

The key factors that drive the growth of the Gynecological Cancer Drugs Industry are an increase in funding of R&D in the activities of gynecological cancer drugs along with rising in the prevalence of cancer. In addition, the favorable government regulations for therapy are further going to boost the Gynecological Cancer Drugs Market Growth during the forecast period. However, the high cost involved in gene therapy along with unwanted immune responses is likely to hamper the growth of the gynecological cancer drugs market during the forecast period. Conversely, advancements in cancer drug research and the advent of personalized medicine approach are expected to provide numerous opportunities for market growth during the forecast period.

By indication, the indications segment is categorized into uterine cancer, ovarian cancer, vaginal & vulvar cancer, and cervical cancer. The cervical cancer segment dominated the market in 2020 and is expected to remain dominant during the forecast period, owing to a surge in the incidence of cervical cancer among all the gynecological cancers.

Depending on therapeutic modality, the market is divided into chemotherapy, targeted therapy, and hormonal therapy. The targeted therapy segment dominated the market in 2020 and is expected to remain dominant during the forecast period, owing to the increased benefits of targeted therapy over chemotherapy.

The Gynecological Cancer Drugs Industry is segmented into therapeutic modality, indication, and region. By therapeutic modality, the market is divided into chemotherapy, targeted therapy, and hormonal therapy. The indications segment is categorized into uterine cancer, ovarian cancer, vaginal & vulvar cancer, and cervical cancer. By region, the market is analyzed across North America (U.S., Canada, and Mexico), Europe (Germany, France, Italy, UK, Spain, and the Rest of Europe), Asia-Pacific (China, Japan, Australia, India, South Korea, and Rest of Asia-Pacific), and LAMEA (Brazil, South Africa, Saudi Arabia, and Rest of LAMEA).

By region, Gynecological Cancer Drugs Market Analysis is done across North America, Europe, Asia-Pacific, and LAMEA. North America has the highest Gynecological Cancer Drugs Market Share, in 2020. Owing to significant investments in research and advancements in technology, the Asia-Pacific market is estimated to reach $5654.88 million at a significant CAGR of 7.1% in 2030. The presence of a large population base, government initiatives to improve healthcare infrastructure, and an increase in healthcare expenditure are the key driving factors that boost the gynecological cancer drugs market in the region.

KEY FINDINGS OF THE STUDY

On the basis of therapeutic modality, the targeted therapy segment dominated the market in 2020 and is expected to continue this trend during the forecast period.

On the basis of indication, the cervical cancer segment dominated the market in 2020 and is expected to continue this trend during the forecast period.

Region-wise, North America garnered the largest revenue share in 2020. However, Asia-Pacific is anticipated to grow at the highest CAGR during the forecast period.

 

 

 

Overview

Cancer refers to a specific group of disorders that lead to abnormal cell growth within any part of the body. This growth may even spread to other body parts. Cancer is named after the body part in which it originates, so gynecological cancer refers to a group of cancers that affect the reproductive organs of a female. Gynecological cancers include cancer in the uterus, endometrium, ovary, peritoneum, fallopian tubes, vagina, vulva, cervix, and muscle &tissue supporting the uterus.

The key factors that drive the market growth include, the high incidence of gynecological cancers, growth in the importance of targeted drug therapies, an increase in investment from government, public, &private sectors for cancer treatment, and a surge in the number of product approval for gynecological cancer drugs drive the market growth. However, the high cost of drug development and the threat of failure & adverse effects of cancer drug therapy on a patient’s body restrain this growth. The advancement of cancer drug research and the advent of personalized medicine approaches are expected to provide numerous opportunities for market growth during the forecast period.

The gynecological cancer drugs market is segmented into therapeutic modality, indication, and region. By therapeutic modality, the market is divided into chemotherapy, targeted therapy, and hormonal therapy. The indications segment is categorized into uterine cancer, ovarian cancer, vaginal & vulvar cancer, and cervical cancer. By region, the market is analyzed across North America (U.S., Canada, and Mexico), Europe (Germany, France, Italy, UK, Spain, and Rest of Europe), Asia-Pacific (China, Japan, Australia, India, South Korea, and Rest of Asia-Pacific), and LAMEA (Brazil, South Africa, Saudi Arabia, and Rest of LAMEA).

The major companies profiled in this report include Apotex Inc., AstraZeneca Plc, Bristol-Myers Squibb Company, Eli Lilly and Company, F. Hoffmann-La Roche AG, GlaxoSmithKline plc, Merck & Co., Inc., Novartis AG, Pfizer Inc., Teva Pharmaceutical Industries Ltd.

Key Benefits For Stakeholders

This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the pneumonia testing market analysis from 2020 to 2030 to identify the prevailing pneumonia testing market opportunities.

The market research is offered along with information related to key drivers, restraints, and opportunities.

Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.

In-depth analysis of the pneumonia testing market segmentation assists to determine the prevailing market opportunities.

Major countries in each region are mapped according to their revenue contribution to the global market.

Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.

The report includes the analysis of the regional as well as global pneumonia testing market trends, key players, market segments, application areas, and market growth strategies.

Key Market Segments

TEVA PHARMACEUTICAL INDUSTRIES LT

Scope of Gynecological Cancer Drugs Market Report

1.1.Report description

1.2.Key market segments

1.3.Key benefits to the stakeholders

1.4.Research Methodology

1.4.1.Secondary research

1.4.2.Primary research

1.4.3.Analyst tools and models

2.1.Key findings of the study

2.2.CXO Perspective

3.1.Market definition and scope

3.2.Key findings

3.2.1.Top investment pockets

3.3.Porter’s five forces analysis

3.4.Top player positioning

3.5.Market dynamics

3.5.1.Drivers

3.5.2.Restraints

3.5.3.Opportunities

3.6.COVID-19 Impact Analysis on the market

4.1 Overview

4.1.1 Market size and forecast

4.2 Chemotherapy

4.2.1 Key market trends, growth factors and opportunities

4.2.2 Market size and forecast, by region

4.2.3 Market analysis by country

4.3 Targeted Therapy

4.3.1 Key market trends, growth factors and opportunities

4.3.2 Market size and forecast, by region

4.3.3 Market analysis by country

4.4 Hormonal Therapy

4.4.1 Key market trends, growth factors and opportunities

4.4.2 Market size and forecast, by region

4.4.3 Market analysis by country

5.1 Overview

5.1.1 Market size and forecast

5.2 Cervical Cancer

5.2.1 Key market trends, growth factors and opportunities

5.2.2 Market size and forecast, by region

5.2.3 Market analysis by country

5.3 Uterine Cancer

5.3.1 Key market trends, growth factors and opportunities

5.3.2 Market size and forecast, by region

5.3.3 Market analysis by country

5.4 Ovarian Cancer

5.4.1 Key market trends, growth factors and opportunities

5.4.2 Market size and forecast, by region

5.4.3 Market analysis by country

5.5 Vaginal & Vulvar Cancer

5.5.1 Key market trends, growth factors and opportunities

5.5.2 Market size and forecast, by region

5.5.3 Market analysis by country

6.1 Overview

6.1.1 Market size and forecast

6.2 North America

6.2.1 Key trends and opportunities

6.2.2 North America Market size and forecast, by By Therapeutic Modality

6.2.3 North America Market size and forecast, by By Indication

6.2.4 North America Market size and forecast, by country

6.2.4.1 U.S.

6.2.4.1.1 Market size and forecast, by By Therapeutic Modality

6.2.4.1.2 Market size and forecast, by By Indication

6.2.4.2 Canada

6.2.4.2.1 Market size and forecast, by By Therapeutic Modality

6.2.4.2.2 Market size and forecast, by By Indication

6.2.4.3 Mexico

6.2.4.3.1 Market size and forecast, by By Therapeutic Modality

6.2.4.3.2 Market size and forecast, by By Indication

6.3 Europe

6.3.1 Key trends and opportunities

6.3.2 Europe Market size and forecast, by By Therapeutic Modality

6.3.3 Europe Market size and forecast, by By Indication

6.3.4 Europe Market size and forecast, by country

6.3.4.1 Germany

6.3.4.1.1 Market size and forecast, by By Therapeutic Modality

6.3.4.1.2 Market size and forecast, by By Indication

6.3.4.2 France

6.3.4.2.1 Market size and forecast, by By Therapeutic Modality

6.3.4.2.2 Market size and forecast, by By Indication

6.3.4.3 U.K.

6.3.4.3.1 Market size and forecast, by By Therapeutic Modality

6.3.4.3.2 Market size and forecast, by By Indication

6.3.4.4 Italy

6.3.4.4.1 Market size and forecast, by By Therapeutic Modality

6.3.4.4.2 Market size and forecast, by By Indication

6.3.4.5 Spain

6.3.4.5.1 Market size and forecast, by By Therapeutic Modality

6.3.4.5.2 Market size and forecast, by By Indication

6.3.4.6 Rest of Europe

6.3.4.6.1 Market size and forecast, by By Therapeutic Modality

6.3.4.6.2 Market size and forecast, by By Indication

6.4 Asia-Pacific

6.4.1 Key trends and opportunities

6.4.2 Asia-Pacific Market size and forecast, by By Therapeutic Modality

6.4.3 Asia-Pacific Market size and forecast, by By Indication

6.4.4 Asia-Pacific Market size and forecast, by country

6.4.4.1 Japan

6.4.4.1.1 Market size and forecast, by By Therapeutic Modality

6.4.4.1.2 Market size and forecast, by By Indication

6.4.4.2 China

6.4.4.2.1 Market size and forecast, by By Therapeutic Modality

6.4.4.2.2 Market size and forecast, by By Indication

6.4.4.3 Australia

6.4.4.3.1 Market size and forecast, by By Therapeutic Modality

6.4.4.3.2 Market size and forecast, by By Indication

6.4.4.4 India

6.4.4.4.1 Market size and forecast, by By Therapeutic Modality

6.4.4.4.2 Market size and forecast, by By Indication

6.4.4.5 South Korea

6.4.4.5.1 Market size and forecast, by By Therapeutic Modality

6.4.4.5.2 Market size and forecast, by By Indication

6.4.4.6 Rest Of Asia Pacific

6.4.4.6.1 Market size and forecast, by By Therapeutic Modality

6.4.4.6.2 Market size and forecast, by By Indication

6.5 LAMEA

6.5.1 Key trends and opportunities

6.5.2 LAMEA Market size and forecast, by By Therapeutic Modality

6.5.3 LAMEA Market size and forecast, by By Indication

6.5.4 LAMEA Market size and forecast, by country

6.5.4.1 Brazil

6.5.4.1.1 Market size and forecast, by By Therapeutic Modality

6.5.4.1.2 Market size and forecast, by By Indication

6.5.4.2 Saudi Arabia

6.5.4.2.1 Market size and forecast, by By Therapeutic Modality

6.5.4.2.2 Market size and forecast, by By Indication

6.5.4.3 South Africa

6.5.4.3.1 Market size and forecast, by By Therapeutic Modality

6.5.4.3.2 Market size and forecast, by By Indication

6.5.4.4 Rest of LAMEA

6.5.4.4.1 Market size and forecast, by By Therapeutic Modality

6.5.4.4.2 Market size and forecast, by By Indication

7.1. Introduction

7.2. Top winning strategies

7.3. Product Mapping of Top 10 Player

7.4. Competitive Dashboard

7.5. Competitive Heatmap

7.6. Key developments

8.1 APOTEX INC

8.1.1 Company overview

8.1.2 Company snapshot

8.1.3 Operating business segments

8.1.4 Product portfolio

8.1.5 Business performance

8.1.6 Key strategic moves and developments

8.2 ASTRAZENECA PLC

8.2.1 Company overview

8.2.2 Company snapshot

8.2.3 Operating business segments

8.2.4 Product portfolio

8.2.5 Business performance

8.2.6 Key strategic moves and developments

8.3 BRISTOL-MYERS SQUIBB COMPANY

8.3.1 Company overview

8.3.2 Company snapshot

8.3.3 Operating business segments

8.3.4 Product portfolio

8.3.5 Business performance

8.3.6 Key strategic moves and developments

8.4 ELI LILLY AND COMPANY

8.4.1 Company overview

8.4.2 Company snapshot

8.4.3 Operating business segments

8.4.4 Product portfolio

8.4.5 Business performance

8.4.6 Key strategic moves and developments

8.5 F. HOFFMANN-LA ROCHE LTD

8.5.1 Company overview

8.5.2 Company snapshot

8.5.3 Operating business segments

8.5.4 Product portfolio

8.5.5 Business performance

8.5.6 Key strategic moves and developments

8.6 GLAXOSMITHKLINE PLC

8.6.1 Company overview

8.6.2 Company snapshot

8.6.3 Operating business segments

8.6.4 Product portfolio

8.6.5 Business performance

8.6.6 Key strategic moves and developments

8.7 MERCK & CO., INC

8.7.1 Company overview

8.7.2 Company snapshot

8.7.3 Operating business segments

8.7.4 Product portfolio

8.7.5 Business performance

8.7.6 Key strategic moves and developments

8.8 NOVARTIS AG

8.8.1 Company overview

8.8.2 Company snapshot

8.8.3 Operating business segments

8.8.4 Product portfolio

8.8.5 Business performance

8.8.6 Key strategic moves and developments

8.9 PFIZER INC

8.9.1 Company overview

8.9.2 Company snapshot

8.9.3 Operating business segments

8.9.4 Product portfolio

8.9.5 Business performance

8.9.6 Key strategic moves and developments

8.10 TEVA PHARMACEUTICAL INDUSTRIES LTD

8.10.1 Company overview

8.10.2 Company snapshot

8.10.3 Operating business segments

8.10.4 Product portfolio

8.10.5 Business performance

8.10.6 Key strategic moves and development

LIST OF TABLES

TABLE 1. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET, BY BY THERAPEUTIC MODALITY, 2020-2030,($MILLION)

TABLE 2. GYNECOLOGICAL CANCER DRUGS MARKET REVENUE, FOR CHEMOTHERAPY, BY REGION , 2020-2030,($MILLION)

TABLE 3. GYNECOLOGICAL CANCER DRUGS MARKET CHEMOTHERAPY BY COUNTRY, 2020-2030,($MILLION)

TABLE 4. GYNECOLOGICAL CANCER DRUGS MARKET REVENUE, FOR TARGETED THERAPY, BY REGION , 2020-2030,($MILLION)

TABLE 5. GYNECOLOGICAL CANCER DRUGS MARKET TARGETED THERAPY BY COUNTRY, 2020-2030,($MILLION)

TABLE 6. GYNECOLOGICAL CANCER DRUGS MARKET REVENUE, FOR HORMONAL THERAPY, BY REGION , 2020-2030,($MILLION)

TABLE 7. GYNECOLOGICAL CANCER DRUGS MARKET HORMONAL THERAPY BY COUNTRY, 2020-2030,($MILLION)

TABLE 8. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET, BY BY INDICATION, 2020-2030,($MILLION)

TABLE 9. GYNECOLOGICAL CANCER DRUGS MARKET REVENUE, FOR CERVICAL CANCER, BY REGION , 2020-2030,($MILLION)

TABLE 10. GYNECOLOGICAL CANCER DRUGS MARKET CERVICAL CANCER BY COUNTRY, 2020-2030,($MILLION)

TABLE 11. GYNECOLOGICAL CANCER DRUGS MARKET REVENUE, FOR UTERINE CANCER, BY REGION , 2020-2030,($MILLION)

TABLE 12. GYNECOLOGICAL CANCER DRUGS MARKET UTERINE CANCER BY COUNTRY, 2020-2030,($MILLION)

TABLE 13. GYNECOLOGICAL CANCER DRUGS MARKET REVENUE, FOR OVARIAN CANCER, BY REGION , 2020-2030,($MILLION)

TABLE 14. GYNECOLOGICAL CANCER DRUGS MARKET OVARIAN CANCER BY COUNTRY, 2020-2030,($MILLION)

TABLE 15. GYNECOLOGICAL CANCER DRUGS MARKET REVENUE, FOR VAGINAL & VULVAR CANCER, BY REGION , 2020-2030,($MILLION)

TABLE 16. GYNECOLOGICAL CANCER DRUGS MARKET VAGINAL & VULVAR CANCER BY COUNTRY, 2020-2030,($MILLION)

TABLE 17. GYNECOLOGICAL CANCER DRUGS MARKET, BY REGION, 2020-2030,($MILLION)

TABLE 18. NORTH AMERICA GYNECOLOGICAL CANCER DRUGS MARKET, BY BY THERAPEUTIC MODALITY, 2020-2030,($MILLION)

TABLE 19. NORTH AMERICA GYNECOLOGICAL CANCER DRUGS MARKET, BY BY INDICATION, 2020-2030,($MILLION)

TABLE 20. NORTH AMERICA GYNECOLOGICAL CANCER DRUGS MARKET, BY COUNTRY, 2020-2030,($MILLION)

TABLE 21. U.S. GYNECOLOGICAL CANCER DRUGS MARKET BY BY THERAPEUTIC MODALITY 2020-2030,($MILLION)

TABLE 22. U.S. GYNECOLOGICAL CANCER DRUGS MARKET BY BY INDICATION 2020-2030,($MILLION)

TABLE 23. CANADA GYNECOLOGICAL CANCER DRUGS MARKET BY BY THERAPEUTIC MODALITY 2020-2030,($MILLION)

TABLE 24. CANADA GYNECOLOGICAL CANCER DRUGS MARKET BY BY INDICATION 2020-2030,($MILLION)

TABLE 25. MEXICO GYNECOLOGICAL CANCER DRUGS MARKET BY BY THERAPEUTIC MODALITY 2020-2030,($MILLION)

TABLE 26. MEXICO GYNECOLOGICAL CANCER DRUGS MARKET BY BY INDICATION 2020-2030,($MILLION)

TABLE 27. EUROPE GYNECOLOGICAL CANCER DRUGS MARKET, BY BY THERAPEUTIC MODALITY, 2020-2030,($MILLION)

TABLE 28. EUROPE GYNECOLOGICAL CANCER DRUGS MARKET, BY BY INDICATION, 2020-2030,($MILLION)

TABLE 29. EUROPE GYNECOLOGICAL CANCER DRUGS MARKET, BY COUNTRY, 2020-2030,($MILLION)

TABLE 30. GERMANY GYNECOLOGICAL CANCER DRUGS MARKET BY BY THERAPEUTIC MODALITY 2020-2030,($MILLION)

TABLE 31. GERMANY GYNECOLOGICAL CANCER DRUGS MARKET BY BY INDICATION 2020-2030,($MILLION)

TABLE 32. FRANCE GYNECOLOGICAL CANCER DRUGS MARKET BY BY THERAPEUTIC MODALITY 2020-2030,($MILLION)

TABLE 33. FRANCE GYNECOLOGICAL CANCER DRUGS MARKET BY BY INDICATION 2020-2030,($MILLION)

TABLE 34. U.K. GYNECOLOGICAL CANCER DRUGS MARKET BY BY THERAPEUTIC MODALITY 2020-2030,($MILLION)

TABLE 35. U.K. GYNECOLOGICAL CANCER DRUGS MARKET BY BY INDICATION 2020-2030,($MILLION)

TABLE 36. ITALY GYNECOLOGICAL CANCER DRUGS MARKET BY BY THERAPEUTIC MODALITY 2020-2030,($MILLION)

TABLE 37. ITALY GYNECOLOGICAL CANCER DRUGS MARKET BY BY INDICATION 2020-2030,($MILLION)

TABLE 38. SPAIN GYNECOLOGICAL CANCER DRUGS MARKET BY BY THERAPEUTIC MODALITY 2020-2030,($MILLION)

TABLE 39. SPAIN GYNECOLOGICAL CANCER DRUGS MARKET BY BY INDICATION 2020-2030,($MILLION)

TABLE 40. REST OF EUROPE GYNECOLOGICAL CANCER DRUGS MARKET BY BY THERAPEUTIC MODALITY 2020-2030,($MILLION)

TABLE 41. REST OF EUROPE GYNECOLOGICAL CANCER DRUGS MARKET BY BY INDICATION 2020-2030,($MILLION)

TABLE 42. ASIA-PACIFIC GYNECOLOGICAL CANCER DRUGS MARKET, BY BY THERAPEUTIC MODALITY, 2020-2030,($MILLION)

TABLE 43. ASIA-PACIFIC GYNECOLOGICAL CANCER DRUGS MARKET, BY BY INDICATION, 2020-2030,($MILLION)

TABLE 44. ASIA-PACIFIC GYNECOLOGICAL CANCER DRUGS MARKET, BY COUNTRY, 2020-2030,($MILLION)

TABLE 45. JAPAN GYNECOLOGICAL CANCER DRUGS MARKET BY BY THERAPEUTIC MODALITY 2020-2030,($MILLION)

TABLE 46. JAPAN GYNECOLOGICAL CANCER DRUGS MARKET BY BY INDICATION 2020-2030,($MILLION)

TABLE 47. CHINA GYNECOLOGICAL CANCER DRUGS MARKET BY BY THERAPEUTIC MODALITY 2020-2030,($MILLION)

TABLE 48. CHINA GYNECOLOGICAL CANCER DRUGS MARKET BY BY INDICATION 2020-2030,($MILLION)

TABLE 49. AUSTRALIA GYNECOLOGICAL CANCER DRUGS MARKET BY BY THERAPEUTIC MODALITY 2020-2030,($MILLION)

TABLE 50. AUSTRALIA GYNECOLOGICAL CANCER DRUGS MARKET BY BY INDICATION 2020-2030,($MILLION)

TABLE 51. INDIA GYNECOLOGICAL CANCER DRUGS MARKET BY BY THERAPEUTIC MODALITY 2020-2030,($MILLION)

TABLE 52. INDIA GYNECOLOGICAL CANCER DRUGS MARKET BY BY INDICATION 2020-2030,($MILLION)

TABLE 53. SOUTH KOREA GYNECOLOGICAL CANCER DRUGS MARKET BY BY THERAPEUTIC MODALITY 2020-2030,($MILLION)

TABLE 54. SOUTH KOREA GYNECOLOGICAL CANCER DRUGS MARKET BY BY INDICATION 2020-2030,($MILLION)

TABLE 55. REST OF ASIA PACIFIC GYNECOLOGICAL CANCER DRUGS MARKET BY BY THERAPEUTIC MODALITY 2020-2030,($MILLION)

TABLE 56. REST OF ASIA PACIFIC GYNECOLOGICAL CANCER DRUGS MARKET BY BY INDICATION 2020-2030,($MILLION)

TABLE 57. LAMEA GYNECOLOGICAL CANCER DRUGS MARKET, BY BY THERAPEUTIC MODALITY, 2020-2030,($MILLION)

TABLE 58. LAMEA GYNECOLOGICAL CANCER DRUGS MARKET, BY BY INDICATION, 2020-2030,($MILLION)

TABLE 59. LAMEA GYNECOLOGICAL CANCER DRUGS MARKET, BY COUNTRY, 2020-2030,($MILLION)

TABLE 60. BRAZIL GYNECOLOGICAL CANCER DRUGS MARKET BY BY THERAPEUTIC MODALITY 2020-2030,($MILLION)

TABLE 61. BRAZIL GYNECOLOGICAL CANCER DRUGS MARKET BY BY INDICATION 2020-2030,($MILLION)

TABLE 62. SAUDI ARABIA GYNECOLOGICAL CANCER DRUGS MARKET BY BY THERAPEUTIC MODALITY 2020-2030,($MILLION)

TABLE 63. SAUDI ARABIA GYNECOLOGICAL CANCER DRUGS MARKET BY BY INDICATION 2020-2030,($MILLION)

TABLE 64. SOUTH AFRICA GYNECOLOGICAL CANCER DRUGS MARKET BY BY THERAPEUTIC MODALITY 2020-2030,($MILLION)

TABLE 65. SOUTH AFRICA GYNECOLOGICAL CANCER DRUGS MARKET BY BY INDICATION 2020-2030,($MILLION)

TABLE 66. REST OF LAMEA GYNECOLOGICAL CANCER DRUGS MARKET BY BY THERAPEUTIC MODALITY 2020-2030,($MILLION)

TABLE 67. REST OF LAMEA GYNECOLOGICAL CANCER DRUGS MARKET BY BY INDICATION 2020-2030,($MILLION)

TABLE 68.APOTEX INC: COMPANY SNAPSHOT

TABLE 69.APOTEX INC: OPERATING SEGMENTS

TABLE 70.APOTEX INC: PRODUCT PORTFOLIO

TABLE 71.APOTEX INC: NET SALES,

TABLE 72.APOTEX INC: KEY STRATERGIES

TABLE 73.ASTRAZENECA PLC: COMPANY SNAPSHOT

TABLE 74.ASTRAZENECA PLC: OPERATING SEGMENTS

TABLE 75.ASTRAZENECA PLC: PRODUCT PORTFOLIO

TABLE 76.ASTRAZENECA PLC: NET SALES,

TABLE 77.ASTRAZENECA PLC: KEY STRATERGIES

TABLE 78.BRISTOL-MYERS SQUIBB COMPANY: COMPANY SNAPSHOT

TABLE 79.BRISTOL-MYERS SQUIBB COMPANY: OPERATING SEGMENTS

TABLE 80.BRISTOL-MYERS SQUIBB COMPANY: PRODUCT PORTFOLIO

TABLE 81.BRISTOL-MYERS SQUIBB COMPANY: NET SALES,

TABLE 82.BRISTOL-MYERS SQUIBB COMPANY: KEY STRATERGIES

TABLE 83.ELI LILLY AND COMPANY: COMPANY SNAPSHOT

TABLE 84.ELI LILLY AND COMPANY: OPERATING SEGMENTS

TABLE 85.ELI LILLY AND COMPANY: PRODUCT PORTFOLIO

TABLE 86.ELI LILLY AND COMPANY: NET SALES,

TABLE 87.ELI LILLY AND COMPANY: KEY STRATERGIES

TABLE 88.F. HOFFMANN-LA ROCHE LTD: COMPANY SNAPSHOT

TABLE 89.F. HOFFMANN-LA ROCHE LTD: OPERATING SEGMENTS

TABLE 90.F. HOFFMANN-LA ROCHE LTD: PRODUCT PORTFOLIO

TABLE 91.F. HOFFMANN-LA ROCHE LTD: NET SALES,

TABLE 92.F. HOFFMANN-LA ROCHE LTD: KEY STRATERGIES

TABLE 93.GLAXOSMITHKLINE PLC: COMPANY SNAPSHOT

TABLE 94.GLAXOSMITHKLINE PLC: OPERATING SEGMENTS

TABLE 95.GLAXOSMITHKLINE PLC: PRODUCT PORTFOLIO

TABLE 96.GLAXOSMITHKLINE PLC: NET SALES,

TABLE 97.GLAXOSMITHKLINE PLC: KEY STRATERGIES

TABLE 98.MERCK & CO., INC: COMPANY SNAPSHOT

TABLE 99.MERCK & CO., INC: OPERATING SEGMENTS

TABLE 100.MERCK & CO., INC: PRODUCT PORTFOLIO

TABLE 101.MERCK & CO., INC: NET SALES,

TABLE 102.MERCK & CO., INC: KEY STRATERGIES

TABLE 103.NOVARTIS AG: COMPANY SNAPSHOT

TABLE 104.NOVARTIS AG: OPERATING SEGMENTS

TABLE 105.NOVARTIS AG: PRODUCT PORTFOLIO

TABLE 106.NOVARTIS AG: NET SALES,

TABLE 107.NOVARTIS AG: KEY STRATERGIES

TABLE 108.PFIZER INC: COMPANY SNAPSHOT

TABLE 109.PFIZER INC: OPERATING SEGMENTS

TABLE 110.PFIZER INC: PRODUCT PORTFOLIO

TABLE 111.PFIZER INC: NET SALES,

TABLE 112.PFIZER INC: KEY STRATERGIES

TABLE 113.TEVA PHARMACEUTICAL INDUSTRIES LTD: COMPANY SNAPSHOT

TABLE 114.TEVA PHARMACEUTICAL INDUSTRIES LTD: OPERATING SEGMENTS

TABLE 115.TEVA PHARMACEUTICAL INDUSTRIES LTD: PRODUCT PORTFOLIO

TABLE 116.TEVA PHARMACEUTICAL INDUSTRIES LTD: NET SALES,

TABLE 117.TEVA PHARMACEUTICAL INDUSTRIES LTD: KEY STRATERGIES LIST OF FIGURES

FIGURE 1.GYNECOLOGICAL CANCER DRUGS MARKET SEGMENTATION

FIGURE 2.GYNECOLOGICAL CANCER DRUGS MARKET,2020-2030

FIGURE 3.GYNECOLOGICAL CANCER DRUGS MARKET,2020-2030

FIGURE 4. TOP INVESTMENT POCKETS, BY REGION

FIGURE 5.PORTER FIVE-1

FIGURE 6.PORTER FIVE-2

FIGURE 7.PORTER FIVE-3

FIGURE 8.PORTER FIVE-4

FIGURE 9.PORTER FIVE-5

FIGURE 10.TOP PLAYER POSITIONING

FIGURE 11.GYNECOLOGICAL CANCER DRUGS MARKET:DRIVERS, RESTRAINTS AND OPPORTUNITIES

FIGURE 12.GYNECOLOGICAL CANCER DRUGS MARKET,BY BY THERAPEUTIC MODALITY,2020(%)

FIGURE 13.COMPARATIVE SHARE ANALYSIS OF CHEMOTHERAPY GYNECOLOGICAL CANCER DRUGS MARKET,2020-2030(%)

FIGURE 14.COMPARATIVE SHARE ANALYSIS OF TARGETED THERAPY GYNECOLOGICAL CANCER DRUGS MARKET,2020-2030(%)

FIGURE 15.COMPARATIVE SHARE ANALYSIS OF HORMONAL THERAPY GYNECOLOGICAL CANCER DRUGS MARKET,2020-2030(%)

FIGURE 16.GYNECOLOGICAL CANCER DRUGS MARKET,BY BY INDICATION,2020(%)

FIGURE 17.COMPARATIVE SHARE ANALYSIS OF CERVICAL CANCER GYNECOLOGICAL CANCER DRUGS MARKET,2020-2030(%)

FIGURE 18.COMPARATIVE SHARE ANALYSIS OF UTERINE CANCER GYNECOLOGICAL CANCER DRUGS MARKET,2020-2030(%)

FIGURE 19.COMPARATIVE SHARE ANALYSIS OF OVARIAN CANCER GYNECOLOGICAL CANCER DRUGS MARKET,2020-2030(%)

FIGURE 20.COMPARATIVE SHARE ANALYSIS OF VAGINAL & VULVAR CANCER GYNECOLOGICAL CANCER DRUGS MARKET,2020-2030(%)

FIGURE 21.GYNECOLOGICAL CANCER DRUGS MARKET BY REGION,2020

FIGURE 22.U.S. GYNECOLOGICAL CANCER DRUGS MARKET,2020-2030($MILLION)

FIGURE 23.CANADA GYNECOLOGICAL CANCER DRUGS MARKET,2020-2030($MILLION)

FIGURE 24.MEXICO GYNECOLOGICAL CANCER DRUGS MARKET,2020-2030($MILLION)

FIGURE 25.GERMANY GYNECOLOGICAL CANCER DRUGS MARKET,2020-2030($MILLION)

FIGURE 26.FRANCE GYNECOLOGICAL CANCER DRUGS MARKET,2020-2030($MILLION)

FIGURE 27.U.K. GYNECOLOGICAL CANCER DRUGS MARKET,2020-2030($MILLION)

FIGURE 28.ITALY GYNECOLOGICAL CANCER DRUGS MARKET,2020-2030($MILLION)

FIGURE 29.SPAIN GYNECOLOGICAL CANCER DRUGS MARKET,2020-2030($MILLION)

FIGURE 30.REST OF EUROPE GYNECOLOGICAL CANCER DRUGS MARKET,2020-2030($MILLION)

FIGURE 31.JAPAN GYNECOLOGICAL CANCER DRUGS MARKET,2020-2030($MILLION)

FIGURE 32.CHINA GYNECOLOGICAL CANCER DRUGS MARKET,2020-2030($MILLION)

FIGURE 33.AUSTRALIA GYNECOLOGICAL CANCER DRUGS MARKET,2020-2030($MILLION)

FIGURE 34.INDIA GYNECOLOGICAL CANCER DRUGS MARKET,2020-2030($MILLION)

FIGURE 35.SOUTH KOREA GYNECOLOGICAL CANCER DRUGS MARKET,2020-2030($MILLION)

FIGURE 36.REST OF ASIA PACIFIC GYNECOLOGICAL CANCER DRUGS MARKET,2020-2030($MILLION)

FIGURE 37.BRAZIL GYNECOLOGICAL CANCER DRUGS MARKET,2020-2030($MILLION)

FIGURE 38.SAUDI ARABIA GYNECOLOGICAL CANCER DRUGS MARKET,2020-2030($MILLION)

FIGURE 39.SOUTH AFRICA GYNECOLOGICAL CANCER DRUGS MARKET,2020-2030($MILLION)

FIGURE 40.REST OF LAMEA GYNECOLOGICAL CANCER DRUGS MARKET,2020-2030($MILLION)

FIGURE 41. TOP WINNING STRATEGIES, BY YEAR

FIGURE 42. TOP WINNING STRATEGIES, BY DEVELOPMENT

FIGURE 43. TOP WINNING STRATEGIES, BY COMPANY

FIGURE 44.PRODUCT MAPPING OF TOP 10 PLAYERS

FIGURE 45.COMPETITIVE DASHBOARD

FIGURE 46.COMPETITIVE HEATMAP OF TOP 10 KEY PLAYERS

FIGURE 47.APOTEX INC.: NET SALES ,($MILLION)

FIGURE 48.ASTRAZENECA PLC.: NET SALES ,($MILLION)

FIGURE 49.BRISTOL-MYERS SQUIBB COMPANY.: NET SALES ,($MILLION)

FIGURE 50.ELI LILLY AND COMPANY.: NET SALES ,($MILLION)

FIGURE 51.F. HOFFMANN-LA ROCHE LTD.: NET SALES ,($MILLION)

FIGURE 52.GLAXOSMITHKLINE PLC.: NET SALES ,($MILLION)

FIGURE 53.MERCK & CO., INC.: NET SALES ,($MILLION)

FIGURE 54.NOVARTIS AG.: NET SALES ,($MILLION)

FIGURE 55.PFIZER INC.: NET SALES ,($MILLION)

FIGURE 56.TEVA PHARMACEUTICAL INDUSTRIES LTD.: NET SALES ,($MILLION